Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for N-acetylcysteine  COVID-19 treatment studies for N-acetylcys..  C19 studies: N-acetylcys..  N-acetylcys..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Other Treatments Global Adoption
Outcomes in COVID-19 N-acetylcysteine studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
All studies   Exclusions   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   Cases   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 20% 19 25,033 Improvement, Studies, Patients Relative Risk Mortality 22% 15 24,571 Ventilation -7% 5 546 ICU admission 1% 5 1,364 Hospitalization 15% 8 965 Recovery 41% 5 1,426 Cases 26% 1 0 RCTs 16% 8 932 RCT mortality 16% 6 581 Peer-reviewed 21% 17 22,565 Prophylaxis 26% 1 0 Early 21% 2 416 Late 20% 16 24,617 N-acetylcysteine for COVID-19 c19early.org/na Jun 2023 FavorsN-acetylcysteine Favorscontrol after exclusions
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Pellegrini 52% 0.48 [0.33-0.70] death 138 (n) 726 (n) Pourhoseingholi 11% 0.89 [0.68-1.18] death 65/309 274/2,159 Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 STORM Faverio (PSW) -19% 1.19 [0.85-1.66] death 91/572 44/329 Ramadhan -135% 2.35 [0.33-16.9] death 11/75 1/16 Izquierdo 26% 0.74 [0.63-0.88] death 136/2,071 1,935/17,137 Delić (RCT) 10% 0.90 [0.63-1.30] death 21/39 31/52 Intubated patients Fariña-González 39% 0.61 [0.34-1.09] death 10/38 44/102 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] death 4/42 4/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] death 10/20 15/20 ICU patients Çavuş (ICU) -13% 1.13 [0.85-1.50] death 52/97 44/93 ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] death 25/72 28/68 ICU patients Tau​2​ = 0.05, I​2​ = 66.2%, p = 0.008 Late treatment 20% 0.80 [0.68-0.94] 449/3,677 2,458/20,940 20% improvement Huh 26% 0.74 [0.68-0.80] cases population-based cohort Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Prophylaxis 26% 0.74 [0.68-0.80] 26% improvement All studies 20% 0.80 [0.71-0.90] 449/3,962 2,459/21,071 20% improvement 19 N-acetylcysteine COVID-19 studies c19early.org/na Jun 2023 Tau​2​ = 0.03, I​2​ = 64.1%, p = 0.00032 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Pellegrini 52% 0.48 [0.33-0.70] death 138 (n) 726 (n) Pourhoseingholi 11% 0.89 [0.68-1.18] death 65/309 274/2,159 Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 STORM Faverio (PSW) -19% 1.19 [0.85-1.66] death 91/572 44/329 Delić (RCT) 10% 0.90 [0.63-1.30] death 21/39 31/52 Intubated patients Fariña-González 39% 0.61 [0.34-1.09] death 10/38 44/102 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] death 4/42 4/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] death 10/20 15/20 ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] death 25/72 28/68 ICU patients Tau​2​ = 0.07, I​2​ = 67.6%, p = 0.0085 Late treatment 24% 0.76 [0.62-0.93] 250/1,434 478/3,694 24% improvement Huh 26% 0.74 [0.68-0.80] cases population-based cohort Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Prophylaxis 26% 0.74 [0.68-0.80] 26% improvement All studies 23% 0.77 [0.68-0.89] 250/1,719 479/3,825 23% improvement 16 N-acetylcysteine COVID-19 studies after exclusions c19early.org/na Jun 2023 Tau​2​ = 0.03, I​2​ = 64.3%, p = 0.0003 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) -3% 1.03 [0.41-2.27] 9/67 9/68 Improvement, RR [CI] Treatment Control Pellegrini 52% 0.48 [0.33-0.70] 138 (n) 726 (n) Pourhoseingholi 11% 0.89 [0.68-1.18] 65/309 274/2,159 Taher (DB RCT) 18% 0.82 [0.43-1.58] 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] 1/24 3/22 STORM Faverio (PSW) -19% 1.19 [0.85-1.66] 91/572 44/329 Ramadhan -135% 2.35 [0.33-16.9] 11/75 1/16 Izquierdo 26% 0.74 [0.63-0.88] 136/2,071 1,935/17,137 Delić (RCT) 10% 0.90 [0.63-1.30] 21/39 31/52 Intubated patients Fariña-González 39% 0.61 [0.34-1.09] 10/38 44/102 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] 4/42 4/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] 10/20 15/20 ICU patients Çavuş (ICU) -13% 1.13 [0.85-1.50] 52/97 44/93 ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] 25/72 28/68 ICU patients Tau​2​ = 0.09, I​2​ = 68.3%, p = 0.02 Late treatment 22% 0.78 [0.63-0.96] 449/3,653 2,458/20,918 22% improvement All studies 22% 0.78 [0.63-0.96] 449/3,653 2,458/20,918 22% improvement 15 N-acetylcysteine COVID-19 mortality results c19early.org/na Jun 2023 Tau​2​ = 0.09, I​2​ = 68.3%, p = 0.02 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) -16% 1.16 [0.59-2.01] 16/67 14/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 14% 0.86 [0.53-1.40] 18/47 20/45 Avdeev 77% 0.23 [0.03-1.90] 1/24 4/22 Mousapour (DB RCT) 27% 0.73 [0.28-1.93] 6/42 8/41 Çavuş (ICU) -20% 1.20 [0.91-1.58] 55/97 44/93 ICU patients Tau​2​ = 0.00, I​2​ = 2.4%, p = 0.6 Late treatment -7% 1.07 [0.85-1.34] 96/277 90/269 7% increased risk All studies -7% 1.07 [0.85-1.34] 96/277 90/269 7% increased risk 5 N-acetylcysteine COVID-19 mechanical ventilation results c19early.org/na Jun 2023 Tau​2​ = 0.00, I​2​ = 2.4%, p = 0.6 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) 9% 0.91 [0.59-1.28] 29/67 32/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 20% 0.80 [0.44-1.47] 47 (n) 45 (n) Avdeev 77% 0.23 [0.03-1.90] 1/24 4/22 STORM Faverio (PSW) -34% 1.34 [0.97-1.84] 107/572 46/329 Çavuş (ICU) 12% 0.88 [0.55-1.39] 97 (n) 93 (n) ICU patients Tau​2​ = 0.03, I​2​ = 34.2%, p = 0.92 Late treatment 1% 0.99 [0.75-1.29] 137/807 82/557 1% improvement All studies 1% 0.99 [0.75-1.29] 137/807 82/557 1% improvement 5 N-acetylcysteine COVID-19 ICU results c19early.org/na Jun 2023 Tau​2​ = 0.03, I​2​ = 34.2%, p = 0.92 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% improvement de Alencar (DB RCT) -10% 1.10 [0.37-3.23] hosp. time 67 (n) 68 (n) Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Taher (DB RCT) 33% 0.67 [0.31-1.45] hosp. time 47 (n) 45 (n) Avdeev 15% 0.85 [0.75-0.96] hosp. time 24 (n) 22 (n) Rahimi (SB RCT) 8% 0.92 [0.68-1.26] hosp. time 20 (n) 20 (n) ICU patients Çavuş (ICU) 13% 0.87 [0.74-1.02] hosp. time 97 (n) 93 (n) ICU patients Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 15% 0.85 [0.80-0.91] 0/279 0/270 15% improvement All studies 15% 0.85 [0.79-0.90] 0/564 1/401 15% improvement 8 N-acetylcysteine COVID-19 hospitalization results c19early.org/na Jun 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.33 Early treatment 80% 0.20 [0.01-4.85] 0/229 1/76 80% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Pellegrini 52% 0.48 [0.33-0.70] death 138 (n) 726 (n) Pourhoseingholi 11% 0.89 [0.68-1.18] death 65/309 274/2,159 Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 STORM Faverio (PSW) -19% 1.19 [0.85-1.66] death 91/572 44/329 Ramadhan -135% 2.35 [0.33-16.9] death 11/75 1/16 Izquierdo 26% 0.74 [0.63-0.88] death 136/2,071 1,935/17,137 Delić (RCT) 10% 0.90 [0.63-1.30] death 21/39 31/52 Intubated patients Fariña-González 39% 0.61 [0.34-1.09] death 10/38 44/102 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] death 4/42 4/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] death 10/20 15/20 ICU patients Çavuş (ICU) -13% 1.13 [0.85-1.50] death 52/97 44/93 ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] death 25/72 28/68 ICU patients Tau​2​ = 0.09, I​2​ = 68.3%, p = 0.02 Late treatment 22% 0.78 [0.63-0.96] 449/3,653 2,458/20,918 22% improvement All studies 22% 0.78 [0.63-0.96] 449/3,882 2,459/20,994 22% improvement 16 N-acetylcysteine COVID-19 serious outcomes c19early.org/na Jun 2023 Tau​2​ = 0.09, I​2​ = 66.6%, p = 0.017 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 83% 0.17 [0.13-0.24] no recov. 229 (n) 75 (n) CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Early treatment 83% 0.17 [0.13-0.24] 0/229 0/75 83% improvement Gaynitdinova (RCT) 51% 0.49 [0.32-0.75] Ct imp. 24 (n) 22 (n) Improvement, RR [CI] Treatment Control Taher (DB RCT) 15% 0.85 [0.60-1.22] no recov. 25/47 28/45 STORM Faverio (PSW) 1% 0.99 [0.81-1.20] no disch. 180/572 105/329 Mousapour (DB RCT) 5% 0.95 [0.74-1.21] no disch. 31/42 32/41 Tau​2​ = 0.04, I​2​ = 66.4%, p = 0.14 Late treatment 17% 0.83 [0.65-1.06] 236/685 165/437 17% improvement All studies 41% 0.59 [0.32-1.09] 236/914 165/512 41% improvement 5 N-acetylcysteine COVID-19 recovery results c19early.org/na Jun 2023 Tau​2​ = 0.48, I​2​ = 95.7%, p = 0.094 ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huh 26% 0.74 [0.68-0.80] cases population-based cohort Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Prophylaxis 26% 0.74 [0.68-0.80] 26% improvement All studies 26% 0.74 [0.68-0.80] 26% improvement 1 N-acetylcysteine COVID-19 case result c19early.org/na Jun 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.33 Early treatment 80% 0.20 [0.01-4.85] 0/229 1/76 80% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Delić (RCT) 10% 0.90 [0.63-1.30] death 21/39 31/52 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] death 4/42 4/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] death 10/20 15/20 ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] death 25/72 28/68 ICU patients Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00027 Late treatment 16% 0.84 [0.77-0.92] 81/311 101/316 16% improvement All studies 16% 0.84 [0.77-0.92] 81/540 102/392 16% improvement 8 N-acetylcysteine COVID-19 Randomized Controlled Trials c19early.org/na Jun 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00025 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) -3% 1.03 [0.41-2.27] 9/67 9/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 18% 0.82 [0.43-1.58] 12/47 14/45 Delić (RCT) 10% 0.90 [0.63-1.30] 21/39 31/52 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] 4/42 4/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] 10/20 15/20 ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] 25/72 28/68 ICU patients Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Late treatment 16% 0.84 [0.67-1.04] 81/287 101/294 16% improvement All studies 16% 0.84 [0.67-1.04] 81/287 101/294 16% improvement 6 N-acetylcysteine COVID-19 RCT mortality results c19early.org/na Jun 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Pellegrini 52% 0.48 [0.33-0.70] death 138 (n) 726 (n) Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 STORM Faverio (PSW) -19% 1.19 [0.85-1.66] death 91/572 44/329 Ramadhan -135% 2.35 [0.33-16.9] death 11/75 1/16 Izquierdo 26% 0.74 [0.63-0.88] death 136/2,071 1,935/17,137 Delić (RCT) 10% 0.90 [0.63-1.30] death 21/39 31/52 Intubated patients Fariña-González 39% 0.61 [0.34-1.09] death 10/38 44/102 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] death 4/42 4/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] death 10/20 15/20 ICU patients Çavuş (ICU) -13% 1.13 [0.85-1.50] death 52/97 44/93 ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] death 25/72 28/68 ICU patients Tau​2​ = 0.06, I​2​ = 68.2%, p = 0.01 Late treatment 21% 0.79 [0.65-0.94] 384/3,368 2,184/18,781 21% improvement All studies 21% 0.79 [0.67-0.93] 384/3,653 2,185/18,912 21% improvement 17 N-acetylcysteine COVID-19 peer reviewed studies c19early.org/na Jun 2023 Tau​2​ = 0.05, I​2​ = 64.3%, p = 0.0043 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Altay (DB RCT) 83% 0.17 [0.13-0.24] no recov. 229 (n) 75 (n) CT​1​ Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 de Alencar (DB RCT) -16% 1.16 [0.59-2.01] ventilation 16/67 14/68 de Alencar (DB RCT) 9% 0.91 [0.59-1.28] ICU 29/67 32/68 de Alencar (DB RCT) -12% 1.12 [0.77-1.65] ICU 67 (n) 68 (n) de Alencar (DB RCT) -10% 1.10 [0.37-3.23] hosp. time 67 (n) 68 (n) Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Gaynitdinova (RCT) 51% 0.49 [0.32-0.75] Ct imp. 24 (n) 22 (n) Pellegrini 52% 0.48 [0.33-0.70] death 138 (n) 726 (n) Pourhoseingholi 11% 0.89 [0.68-1.18] death 65/309 274/2,159 Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Taher (DB RCT) 14% 0.86 [0.53-1.40] ventilation 18/47 20/45 Taher (DB RCT) 20% 0.80 [0.44-1.47] ICU 47 (n) 45 (n) Taher (DB RCT) 33% 0.67 [0.31-1.45] hosp. time 47 (n) 45 (n) Taher (DB RCT) 15% 0.85 [0.60-1.22] no recov. 25/47 28/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 Avdeev 77% 0.23 [0.03-1.90] ventilation 1/24 4/22 Avdeev 77% 0.23 [0.03-1.90] ICU 1/24 4/22 Avdeev 15% 0.85 [0.75-0.96] hosp. time 24 (n) 22 (n) STORM Faverio (PSW) -19% 1.19 [0.85-1.66] death 91/572 44/329 STORM Faverio (PSW) -34% 1.34 [0.97-1.84] ICU 107/572 46/329 STORM Faverio (PSW) 1% 0.99 [0.81-1.20] no disch. 180/572 105/329 Ramadhan -135% 2.35 [0.33-16.9] death 11/75 1/16 Izquierdo 26% 0.74 [0.63-0.88] death 136/2,071 1,935/17,137 Delić (RCT) 10% 0.90 [0.63-1.30] death 21/39 31/52 Intubated patients Fariña-González 39% 0.61 [0.34-1.09] death 10/38 44/102 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] death 4/42 4/41 Mousapour (DB RCT) 27% 0.73 [0.28-1.93] ventilation 6/42 8/41 Mousapour (DB RCT) 6% 0.94 [0.67-1.32] no improv. 25/42 26/41 Mousapour (DB RCT) 5% 0.95 [0.74-1.21] no disch. 31/42 32/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] death 10/20 15/20 ICU patients Rahimi (SB RCT) 8% 0.92 [0.68-1.26] hosp. time 20 (n) 20 (n) ICU patients Çavuş (ICU) -13% 1.13 [0.85-1.50] death 52/97 44/93 ICU patients Çavuş (ICU) -20% 1.20 [0.91-1.58] ventilation 55/97 44/93 ICU patients Çavuş (ICU) 12% 0.88 [0.55-1.39] ICU 97 (n) 93 (n) ICU patients Çavuş (ICU) 13% 0.87 [0.74-1.02] hosp. time 97 (n) 93 (n) ICU patients Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] death 25/72 28/68 ICU patients Huh 26% 0.74 [0.68-0.80] cases population-based cohort N-acetylcysteine COVID-19 outcomes c19early.org/na Jun 2023 ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Share
Tweet
@CovidAnalysis
FAQ
Public domain CC0 1.0